[
  {
    "symbol": "INCY",
    "price": 60.95,
    "beta": 0.715845,
    "volAvg": 2017251,
    "mktCap": 13597213600,
    "lastDiv": 0,
    "range": "60.5696-86.29",
    "changes": -0.73,
    "companyName": "Incyte Corporation",
    "currency": "USD",
    "cik": "0000879169",
    "isin": "US45337C1027",
    "cusip": "45337C102",
    "exchange": "NASDAQ Global Select",
    "exchangeShortName": "NASDAQ",
    "industry": "Biotechnology",
    "website": "https://www.incyte.com",
    "description": "Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat na√Øve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.",
    "ceo": "Mr. Herve  Hoppenot",
    "sector": "Healthcare",
    "country": "US",
    "fullTimeEmployees": "2324",
    "phone": "302 498 6700",
    "address": "1801 Augustine Cut-Off",
    "city": "Wilmington",
    "state": "DE",
    "zip": "19803",
    "dcfDiff": 2.14464,
    "dcf": 87.8446,
    "image": "https://financialmodelingprep.com/image-stock/INCY.png",
    "ipoDate": "1993-11-04",
    "defaultImage": false,
    "isEtf": false,
    "isActivelyTrading": true,
    "isAdr": false,
    "isFund": false
  }
]